Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

被引：0
|
作者：
Song, Zhengbo [1 ]
Zhang, Yiping [2 ]
Yuz, Xinmin [1 ]
机构：
[1] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Thymidylate synthetase; ros1; pemetrexed; efficacy;
D O I：
10.1016/j.jtho.2016.11.1659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-029
引用
收藏
页码：S1179 / S1180
页数：2
相关论文
共 50 条
  • [21] A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
    Qiang Zhang
    Xiaoli Zhu
    Li Zhang
    Siqing Sun
    Jing Huang
    Yong Lin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 839 - 846
  • [22] A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
    Zhang, Qiang
    Zhu, Xiaoli
    Zhang, Li
    Sun, Siqing
    Huang, Jing
    Lin, Yong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 839 - 846
  • [23] Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
    Minami, Seigo
    Kijima, Takashi
    Takahashi, Ryo
    Kida, Hiroshi
    Nakatani, Takeshi
    Hamaguchi, Masanari
    Takeuchi, Yoshiko
    Nagatomo, Izumi
    Yamamoto, Suguru
    Tachibana, Isao
    Komuta, Kiyoshi
    Kawase, Ichiro
    BMC CANCER, 2012, 12
  • [24] Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Barton, John H.
    Patton, Jeffrey F.
    Zubkus, John D.
    Simons, Lisa
    Griner, Paula
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 841 - 845
  • [25] Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer
    Chen, Ruhua
    Fen, Yan
    Lin, Xubo
    Ma, Tieliang
    Cai, Hourong
    Ding, Hui
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2016, 15 (06) : 815 - 820
  • [26] Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
    Kwon, Ji-Hyun
    Kim, Kui-Jin
    Sung, Ji Hea
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Ji-Won
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Lee, Keun-Wook
    Kim, Jee Hyun
    Bang, Soo-Mee
    Kim, Soyeon
    Yoon, Sung-Soo
    Lee, Jong Seok
    CELLS, 2019, 8 (12)
  • [27] Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer
    Tumolo, S
    Toffoli, G
    Saracchini, S
    Lo Re, G
    Bruschi, G
    Boccieri, MG
    LUNG CANCER, 2001, 34 : S37 - S46
  • [28] The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
    Li, Xiaoqin
    Gu, Guomin
    Soliman, Faris
    Sanders, Andrew J.
    Wang, Xiuli
    Liu, Chunling
    CHEMOTHERAPY, 2018, 63 (04) : 214 - 219
  • [29] Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients
    Chayangsu, Chawalit
    Khorana, Jiraporn
    Charoentum, Chaiyut
    Sriuranpong, Virote
    Patumanond, Jayanton
    Tantraworasin, Apichat
    HEALTHCARE, 2023, 11 (03)
  • [30] First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements
    Ma, Yuxiang
    Zhao, Hongyun
    Xue, Jinhui
    Liu, Li
    Yang, Nong
    Zhang, Yang
    Yang, Haiyan
    Hong, Shaodong
    Xiong, Yi
    Zhang, Zhonghan
    Zeng, Liang
    Pan, Hui
    Zhou, Chunhua
    Zhang, Yongchang
    Wang, Xunqiang
    Han, Xi
    Wan, Xiaojing
    Shao, Yang
    Liu, Jingwen
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Li, Su
    Zhang, Li
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : 238 - 249
12345